A pharmaceutical royalty company that acquires interests in approved and late-stage biopharmaceutical products in exchange for upfront capital to drug developers and research institutions. Its portfolio generates revenue from sales of therapies across areas such as oncology, rare diseases, and immun...
3 members of Congress have disclosed 4 trades in Royalty Pharma PLC Class A (RPRX), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 4 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-04-10 | MICHAEL T. MCCAUL | sell | $1K – $15K |
| 2024-11-15 | Rohit Khanna | sell | $1K – $15K |
| 2022-03-03 | Rohit Khanna | sell | $50K – $100K |
| 2020-12-21 | David P. Roe | sell | $1K – $15K |